DiaCarta, Capstone Health Alliance collaborate to bring diagnostic tests to enhance patient care

DiaCarta has established a strategic collaboration with Capstone Health Alliance. This new collaboration brings together powerful technologies to enhance patient care. DiaCarta’s key product portfolio includes its trailblazing RadTox™ test, a blood test that monitors tumor response & progression following cancer treatment by monitoring changes in cell free circulating DNA (cfDNA) levels. This serves to personalize radiation and chemotherapy, mitigate adverse events, and enhance patient care. The state of Florida has deployed the RadTox™ test statewide to be performed between Radiotherapy or Chemotherapy doses for real time detection of treatment response or resistance.

Read More